PDF(Pubmed)
Abstract：
Information on the financial toxicity experienced by Japanese patients with metastatic renal cell carcinoma (mRCC) is lacking, even though Japan has its own unique public health insurance system. Thus, a web-based survey was conducted to evaluate the financial toxicity experienced by Japanese mRCC patients using the COmprehensive Score for financial Toxicity (COST) tool. This study enrolled Japanese patients who underwent, or were undergoing, systemic therapy for mRCC. The outcomes evaluated were the distribution of COST scores, the correlation between COST and quality of life (QOL) assessed by the Functional Assessment of Cancer Therapy-General (FACT-G) scale, and demographic factors associated with financial toxicity. The median (range) COST score was 19.0 (3.0-36.0). The Pearson correlation coefficient for COST and FACT-G total scores was 0.40. Univariate analysis revealed that not having private health insurance and lower household income per year were significantly associated with lower COST scores. Multivariate analyses showed that age < 65 years and not having private health insurance were significantly associated with lower COST scores. This study revealed that Japanese mRCC patients experience adverse financial impacts even under the universal health insurance coverage system available in Japan, and financial toxicity negatively affects their QOL.
摘要：
缺乏有关日本转移性肾细胞癌（mRCC）患者所经历的财务毒性的信息，尽管日本有自己独特的公共健康保险制度。因此，采用财务毒性综合综合评分(COST)工具进行了一项基于网络的调查,以评估日本mRCC患者所经历的财务毒性.这项研究招募了日本患者，或者正在经历，mRCC的全身治疗。评估的结果是COST分数的分布，通过癌症治疗功能评估（FACT-G）量表评估COST与生活质量（QOL）之间的相关性，以及与金融毒性相关的人口因素。中位数（范围）COST评分为19.0（3.0-36.0）。COST和FACT-G总分的Pearson相关系数为0.40。单变量分析显示，没有私人健康保险和每年家庭收入较低与较低的COST分数显着相关。多变量分析显示，年龄<65岁和没有私人健康保险与较低的COST评分显著相关。这项研究表明，即使在日本可用的全民健康保险覆盖系统下，日本mRCC患者也会受到不利的财务影响，和财务毒性对他们的QOL产生负面影响。
